Supplemental material
Drug Delivery
Volume 24, 2017 - Issue 1
Open access
1,350
Views
7
CrossRef citations to date
0
Altmetric
Research Article
A novel tumor-activated ALA fusion protein for specific inhibition on the growth and invasion of breast cancer cells MDA-MB-231
Xiufeng Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; View further author information
, Xintong Liuc School of Life Science and Technology, China Pharmaceutical University, Nanjing, PR ChinaView further author information
, Suwen Sunchena State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
, Meixia Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
, Chen Shena State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
, Juanjuan Wua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
, Wanli Zhaoa State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; View further author information
, Boyang Yua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; View further author information
& Jihua Liua State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, PR China; ;b Jiangsu Key Laboratory of TCM Evaluation and Translational Research, Department of Biotechnology of TCM, China Pharmaceutical University, Nanjing, PR China; Correspondence[email protected]
View further author information
show allView further author information
Pages 1811-1817
|
Received 19 Sep 2017, Accepted 14 Nov 2017, Published online: 24 Nov 2017
Related Research Data
Novel Delivery Systems for Improving the Clinical Use of Peptides
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Global Cancer Statistics, 2012
Source:
Wiley
Role of uPA/uPAR in the Modulation of Angiogenesis
Source:
S. Karger AG
Global cancer statistics in the year 2000
Source:
Elsevier BV
Scorpion venoms as a potential source of novel cancer therapeutic compounds.
Source:
SAGE Publications
Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer.
Source:
Springer Netherlands
Cancer Statistics, 2016
Source:
Wiley
Formulation, Processing, and Delivery Systems, Third Edition
Source:
CRC Press
A Novel Tumor Targeting Drug Carrier for Optical Imaging and Therapy
Source:
Ivyspring International Publisher
Targeting of peptide conjugated magnetic nanoparticles to urokinase plasminogen activator receptor (uPAR) expressing cells.
Source:
Royal Society of Chemistry (RSC)
ATF-L-VAS is a Candidate for Targeted Tumor Therapy
Source:
Wiley
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme
Source:
Journal of Neurosurgery Publishing Group (JNSPG)
Scorpion venom components as potential candidates for drug development
Source:
Elsevier BV
Current challenges in peptide-based drug discovery
Source:
Frontiers Media SA
Drug carriers for the delivery of therapeutic peptides.
Source:
American Chemical Society (ACS)
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.